Trials / Conditions / Helicobacter Infections

Helicobacter Infections

30 registered clinical trials studyying Helicobacter Infections — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Completed	Helicobacter Pylori Infection and Gastric Diseases in Lao PDR: First Community-Wide Population-Based Study NCT07340593	Zero Helicobacter IGAN Network	—
Unknown	Effectiveness of Rifabutin for Treatment of Helicobacter Pylori NCT04652284	Rabin Medical Center	Phase 3
Completed	Association Between Helicobacter Pylori and Inflammatory Bowel Disease NCT03820284	Assiut University	—
Unknown	A Unique Regimen for Treatment of Helicobacter Pylori Infection NCT03491995	Sherief Abd-Elsalam	Phase 3
Recruiting	A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children NCT03365609	Ying HUANG	N/A
Completed	Specimen Collection Study for H. Pylori Testing NCT02970110	Biomerica	—
Withdrawn	The Effect of Probiotic Combination on Helicobacter Pylori Infection in Children NCT02645201	University Medical Centre Ljubljana	N/A
Completed	Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection NCT02401477	Il-Yang Pharm. Co., Ltd.	Phase 4
Unknown	Endofaster Test for Helicobacter Pylori Detection in Patients on Proton Pump Inhibitor Therapy NCT02126722	Niso Biomed S.R.L.	—
Completed	Helicobacter Pylori and Proton Pump Inhibitor NCT02449941	Asan Medical Center	—
Completed	Efficacy on Helicobacter Pylori Eradication With Two Antibiotic Regimens NCT02395458	Coordinación de Investigación en Salud, Mexico	Phase 4
Completed	Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H. NCT02352701	Il-Yang Pharm. Co., Ltd.	—
Completed	A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment o NCT01219764	American University of Beirut Medical Center	Phase 4
Active Not Recruiting	Helicobacter Pylori Eradication to Prevent Gastric Cancer NCT01133951	Jie-Jun Wang	N/A
Completed	Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients NCT00723502	MerLion Pharmaceuticals GmbH	Phase 2
Completed	Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy NCT00669955	Forest Laboratories	Phase 3
Terminated	Treating H. Pylori in Parkinson's Patients With Motor Fluctuations NCT00664209	University of California, Los Angeles	Phase 3
Completed	First Time in Man Study of Finafloxacin Hydrochloride NCT00483158	MerLion Pharmaceuticals GmbH	Phase 1
Completed	Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication NCT00816140	National Taiwan University Hospital	Phase 4
Completed	Helicobacter Pylori and Acute Alcohol Induced Pancreatitis NCT00490386	Tampere University	—
Completed	Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults. NCT00216450	Janssen Cilag Pharmaceutica S.A.C.I., Greece	Phase 4
Completed	Helicobacter Pylori and Dry Eye NCT00083291	National Eye Institute (NEI)	—
Unknown	Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection NCT00197418	Hamamatsu University	Phase 2 / Phase 3
Unknown	Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori NCT00149084	Hamamatsu University	Phase 3
Completed	Breath Ammonia Method for H. Pylori Detection: Phase II NCT00194688	University of Washington	Phase 2
Completed	Eradication Rates of Helicobacter Pylori and Its Affecting Factors NCT01922505	Seoul National University Bundang Hospital	—
Completed	Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadr NCT01792700	Seoul National University Bundang Hospital	Phase 4
Completed	Infection and Cardiovascular Disease NCT00005547	National Heart, Lung, and Blood Institute (NHLBI)	—
Completed	Inflammation, Infection, and Future Cardiovascular Risk NCT00005496	National Heart, Lung, and Blood Institute (NHLBI)	—
Completed	Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori) NCT00212225	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	—